RN Mobile Menu

Search form





Excluding patients with SCLE from clinical trials because they don't meet SLE criteria may not make much sense, researchers report.


Researchers reporting in the journal Lupus find that a simple walking test can help assess the status of pulmonary disease in patients with systemic lupus erythematosus.

Maria Dall’Era, M.D.

With only one approved biologic agent — 

Maria Dall’Era, M.D.

The treat-to-target paradigm has been utilized in RA and other diseases, but not yet lupus. Treat-to-target guidelines in lupus could be complex, but are needed.

Maria Dall'Era, MD

The development of biologic therapies and other treatments for lupus remains a challenge, but anti-interferon agents that are in development could turn things around.

Paul Sufka M.D.

Belimumab has been a ground-breaking therapy for patients with systemic lupus erythematosus. In this op-ed, Paul Sufka, M.D., reviews recent studies on belimumab which could lead to new uses.

Belimumab combined with standard of care continues to show positive improvements for patients with systemic lupus erythematosus.


Subscribe to Lupus on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.